Navigation Links
New therapy to stop progression of fibrosis
Date:2/14/2014

Scientists from the University of Sheffield have developed a novel antibody-based therapy which targets the progression of life threating kidney fibrosis.

The ground breaking therapy works by blocking the action of a key enzyme and the treatment should also work for lung, liver and heart fibrosis.

The pioneering biological discovery was made by a research team led by Professor Tim Johnson and Dr Phil Watson, from the University's Academic Nephrology Unit in the Department of Infection and Immunity.

The research, conducted in collaboration with MRC Technology, targets a key step in the progression of fibrosis, which has led to the development of a fibrosis therapy programme and exclusive licensing agreement by global biopharmaceutical company UCB.

There is currently no cure for fibrosis, a primary cause of major organ failure, and a complicating factor in chronic diseases such as diabetes and hypertension.

Professor Johnson said: "The development of these therapeutic antibodies is the culmination of 20 years work to identify the role of a key target in the tissue scarring process where it is possible to understand its mechanism of action and then develop a way to specifically target it.

"This is a fantastic example of how MRC Technology can assist in translating laboratory research to the patient. I am delighted that UCB have licensed the humanised antibodies as the company's expertise in antibody development will ensure patients benefit from this new treatment in the shortest time possible."

He added: " It is also extremely important to recognise that this work would not have been possible without support from charities such as Kidney Research UK, Diabetes UK and the Wellcome trust who have all supported this work."

UCB New Medicines Vice President and Head of Immunology, Dr Mark Bodmer, said: "The program focuses on a key area of unmet medical need and we are committed to bringing fibrosis treatment to patients.

"We are excited to be working with MRC Technology and University of Sheffield scientists to build on their work to date in generating and characterising promising therapeutic approaches with the potential for significant patient impact."

Michael Dalrymple, Director of Business Development at MRC Technology, said: "We are delighted to be able to partner this program with UCB and we look forward to working together to ensure the project's commercial success. This program has the potential to not only benefit fibrosis patients and help prevent organ failure, but also enables MRC Technology and its partners to help bring other new research to market."

Revenue made from the licensing agreement will be shared back with the University and will be reinvested to support other collaborative programs within its drug discovery labs.


'/>"/>

Contact: Amy Pullan
a.l.pullan@sheffield.ac.uk
01-142-229-859
University of Sheffield
Source:Eurekalert

Related medicine news :

1. Metal implants may cut chemotherapy side effects, study suggests
2. LA BioMed researchers report on promising new therapy for devastating genetic disorder
3. Skin reactions during radiation therapy preventable
4. What is the safest way to stop postmenopausal hormone therapy?
5. Cancer immunotherapy leader Allison to receive 2014 Szent-Gyorgyi Prize
6. Endocrine Society calls for large-scale studies to evaluate testosterone therapy risks
7. The art and science of cognitive rehabilitation therapy
8. Researchers open door to new HIV therapy
9. Music therapys positive effects on young cancer patients coping skills, social integration
10. Long-term follow-up shows need for new chemotherapy strategies for rectal cancer
11. Dr. Leigh Ann Scott to Open Irving Office to Provide Bio-Identical Hormone Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... DC (PRWEB) , ... June 27, 2017 , ... Children’s ... Best Children’s Hospitals rankings, with its Neonatology program ranking #1 out of more ... was also named to the coveted Honor Roll, a distinction given to the top ...
(Date:6/26/2017)... ... 26, 2017 , ... Dr. Martin Bastuba, MD, FACS, founder ... the Fertility Center of California, is pleased to announce the addition of two ... TESA (percutaneous testicular sperm extraction). These minimally invasive treatments are primarily used to ...
(Date:6/26/2017)... ... June 26, 2017 , ... ... is revolutionizing the way women look and feel about themselves and their sexual ... female sexual dysfunction and urinary leakage head on with a ground breaking medical ...
(Date:6/26/2017)... ... 26, 2017 , ... KICKICO , a protocol built on Ethereum for ... many catastrophic issues within funding campaigns. KICKICO developers are testing the platform, which will ... the raising of funds through the power of many - has been around for ...
(Date:6/25/2017)... ... ... Create a feel-good lyric music video in Final Cut Pro X with ProLyric from Pixel ... in the lyrics to any song. ProLyric flies in the text for each section and ... be added modularly for optimal control. ProLyric makes editing any music video or text-based production ...
Breaking Medicine News(10 mins):
(Date:6/1/2017)... BELL, Pa. , June 1, 2017 ... (PRN) and Veterinarian Recommended Solutions (VRS), and KD Pharma ... investment in Nutriceutical Holdings by KD Pharma Group. KD ... Holdings with the option to acquire the entire company. ... partner in KD. They are committed to growing the ...
(Date:5/26/2017)... 2017  Endo International plc (NASDAQ: ENDP ) ... will represent the Company in a fireside chat at Goldman ... June 13, 2017 at 10:40 a.m. PT / 1:40 p.m. ... Rancho Palos Verdes, CA. ... be available on the Company,s website at http://www.endo.com/investors/overview . ...
(Date:5/22/2017)...  As the specialty pharmacy industry and the ... the revolutionary shift from volume-based to value-based care, ... patient outcomes and shaping the future of the ... from clinical trials and toward data that reveals ... therapy utilization in precise patient populations. Therigy ® ...
Breaking Medicine Technology: